Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece

Angiology

Volumn 63, Issue 3, 2012, Pages 184-193

  Liberopoulos, Evangelos ^a   Vlasserou, Fotini ^b   Mitrogianni, Zoe ^a   Papageorgantas, Ioannis ^b   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b VIANEX SA   (Greece)

Author keywords

cardiovascular risk; cholesterol; Dyslipidemia International Study; high density lipoprotein cholesterol; low density lipoprotein cholesterol; residual risk; statins

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GENDER; GREECE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; SEDENTARY LIFESTYLE; SMOKING; WAIST CIRCUMFERENCE;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84857820914     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711410226     Document Type: Article

References (33)

1. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 ; 14 (suppl 2). S1 - S113 (Pubitemid 47339826)
2. European Heart Network. EuroHeart Work Package 5. Cardiovascular disease prevention in Europe-the unfinished agenda. 2009. http://www.ehnheart.org/ euroheart/publications-wp-5-wp-6.html. Accessed September 28, 2010.
3. Chimonas T, Fanouraki I, Liberopoulos EN, Chimonas E, Elisaf M.. Diverging trends in cardiovascular morbidity and mortality in a low risk population. Eur J Epidemiol. 2009 ; 24 (8). 415-423
4. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M.. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006 ; 27 (13). 1610-1619 (Pubitemid 43954923)
5. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 ; 291 (9). 1071-1080 (Pubitemid 38541684)
6. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 ; 295 (13). 1556-1565
7. Kotseva K, Wood D, De Backer G, de Bacquer D, Pyorala K, Keil U.. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 ; 373 (9667). 929-940
8. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (5). 530-540
9. Kotseva K, Stagmo M, de Bacquer D, De Backer G, Wood D.. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II study. Atherosclerosis. 2008 ; 197 (2). 710-717 (Pubitemid 351417868)
10. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 ; 357 (13). 1301-1310 (Pubitemid 47481452)
11. The IDF consensus worldwide definition of the metabolic syndrome. 2006.http://www.idf.org/webdata/docs/IDF-Meta-def-final.pdf. Accessed December 09, 2010.
12. Dietary guidelines for adults in Greece. Arch Hel Med. 1999 ; 16 (5). 516-524
13. Maron DJ, Fazio S, Linton MF.. Current perspectives on statins. Circulation. 2000 ; 101 (2). 207-213 (Pubitemid 30044262)
14. Roberts WC.. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997 ; 80 (1). 106-107
15. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP.. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin. 2009 ; 25 (10). 2571-2576
16. Hatzitolios AI, Athyros VG, Karagiannis A, et al. Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol. 2009 ; 134 (3). 322-329
17. Gitt A, Drexel H, Feely J, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Cardiovasc Prev Rehabil. 2011 ;:
18. Goodman SG, Langer A, Bastien NR, et al. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol. 2010 ; 26 (9). e331 - e335
19. Elisaf MS, Nikas N.. Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS-Greece survey. Angiology. 2010 ; 61 (5). 465-474
20. Liberopoulos EN, Elisaf MS.. Control of cardiovascular risk factors in outpatients with atherothrombosis in Greece. Atherosclerosis Suppl. 2007 ; 8 (5). 130-131
21. Jafri H, Alsheikh-Ali AA, Karas RH.. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010 ; 153 (12). 800-808
22. Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009 ; 104 (4). 459-463
23. Hermans MP, Castro Cabezas M, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010 ; 26 (2). 445-454
24. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 ; 295 (2). 180-189 (Pubitemid 43076437)
25. Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study-Observational (CALIPSO). Can J Cardiol. 2005 ; 21 (13). 1187-1193 (Pubitemid 43013529)
26. Goff DC, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006 ; 113 (5). 647-656
27. Lairon D.. Intervention studies on Mediterranean diet and cardiovascular risk. Mol Nutr Food Res. 2007 ; 51 (10). 1209-1214 (Pubitemid 350013168)
28. Vardavas CI, Linardakis MK, Hatzis CM, Saris WH, Kafatos HG.. Cardiovascular disease risk factors and dietary habits of farmers from Crete 45 years after the first description of the Mediterranean diet. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (4). 440-446
29. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Stefanadis C.. Status and management of blood lipids in Greek adults and their relation to socio-demographic, lifestyle and dietary factors: the ATTICA Study. Blood lipids distribution in Greece. Atherosclerosis. 2004 ; 173 (2). 353-361 (Pubitemid 38469807)
30. Krobot KJ, Yin DD, Alemao E, Steinhagen-Thiessen E.. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil. 2005 ; 12 (1). 37-45 (Pubitemid 40388291)
31. Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M.. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol. 2010 ; 138 (1). 25-31
32. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM.. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010 ; 121 (9). 1069-1077
33. Liberopoulos EN, Mikhailidis DP, Elisaf MS.. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev. 2005 ; 6 (4). 283-296 (Pubitemid 41581637)